The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Final analysis results from the phase 3 KEYNOTE-522 study.

Peter  Schmid

Employment - Roche (I)

Honoraria - AstraZeneca; Bayer; Bayer; Boehringer Ingelheim; Celgene; Celgene; Eisai; Genentech (Inst); Gilead Sciences Hong Kong; Merck; Novartis; Oncogenex (Inst); Oncogenex (Inst); Pfizer; Puma Biotechnology; Roche; Sanofi; Stemline Therapeutics

Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)

Travel, Accommodations, Expenses - ESMO; SABS

Javier  Cortes

Stock and Other Ownership Interests  - Leuko (I); MAJ3 Capital

Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung; Steamline Therapeutics; Zuellig Pharma

Consulting or Advisory Role - Abbvie; AstraZeneca; Athenex; Bioasis; Biocon; Bioinvent; BioNTech SE; Bliss Biopharmaceutical; Boehringer Ingelheim; Bridgebio; Celgene; Cellestia Biotech; Circle Pharma; Clovis Oncology; Daiichi Sankyo; Delcath Systems; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; Hexagon Bio; HiberCell; Jazz Pharmaceuticals; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Relay Therapeutics; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks

Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)

Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.

Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Merck Sharp&Dhome; Novartis; Pfizer; Roche; Steamline Therapeutics

Rebecca  Dent

Honoraria - AstraZeneca; BioNTech SE; Daiichi Sankyo/Astra Zeneca; DKSH; Eisai; Gilead Sciences; MSD; Novartis; Pfizer; Roche

Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; Gilead Sciences; MSD; Novartis; Pfizer; Roche

Research Funding - AstraZeneca (Inst); Roche (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; MSD; Novartis; Pfizer; Roche

Heather  McArthur

Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; Merck; Moderna Therapeutics; Novartis; Pfizer; Stemline Therapeutics

Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)

Lajos  Pusztai

Stock and Other Ownership Interests  - Ataraxis

Honoraria - Agendia; AstraZeneca; Bristol-Myers Squibb; Merck @ Co; natera; Radionetics

Consulting or Advisory Role - Agendia; AstraZeneca; Bristol Myers Squibb; Merck; Natera; Personalis; Radionetics

Research Funding - Agendia (Inst); AstraZeneca (Inst); Bristol Myers Squibb (Inst); Exact Sciences (Inst); Menarini (Inst); Merck (Inst); Natera (Inst); Personalis (Inst); Pfizer (Inst)

(OPTIONAL) Uncompensated Relationships - Caris Life Sciences; Foundation Medicine

Sherko  Kuemmel

Consulting or Advisory Role - Agendia; Amgen; AstraZeneca; Daiichi Sankyo; Exact Sciences; Gilead Sciences; Hologic; Lilly; MSD Oncology; Novartis; Pfizer; PINK; Roche/Genentech; Seagen; Sonoscape; Stemline Therapeutics; Stryker

Speakers' Bureau - Novartis

Travel, Accommodations, Expenses - Daiichi Sankyo; Gilead Sciences; Roche

(OPTIONAL) Uncompensated Relationships - West German Study Group

Carsten  Denkert

Consulting or Advisory Role - AstraZeneca; BioNTech SE; Daiichi Sankyo; Merck; MSD Oncology

Research Funding - German Breast Group (Inst); Myriad Genetics (Inst)

Patents, Royalties, Other Intellectual Property - Patent EP24210258; Patent WO2010076322A1; Patent WO2015114146A1; Patent WO2020109570A1; VMScope digital pathology software

Yeon Hee  Park

Honoraria - AimedBio; AstraZeneca; BeOne; BMS; Daiichi-Sankyo; Eisai; Gilead Sciences; Helsinn Healthcare; Lilly; MSD; Novartis; Pfizer; Roche; Voronoi Health Analytics

Consulting or Advisory Role - AimedBio; AstraZeneca; BMS; Boryung; Daiichi-Sankyo; Eisai; Gilead Sciences; Helsinn Therapeutics; Jazz Pharmaceuticals; Lilly; Menarini; MSD; Novartis; Pfizer; Roche; Voronoi Health Analytics

Research Funding - AstraZeneca; Boryung; Daewoong Pharmaceutical; Gencurix; Gencurix (Inst); Gilead Sciences; Inocras; Inocras (Inst); Kirin Pharmaceuticals; NGeneBio (Inst); Pfizer; Roche (Inst)

Travel, Accommodations, Expenses - Daiichi Sankyo; Gilad; Helsinn Therapeutics; Jazz Pharmaceuticals; Novartis; Pfizer; Roche

Rina  Hui

Honoraria - Amgen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Johnson & Johnson/Janssen; Lilly; Merck Sharp & Dohme

Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Johnson & Johnson/Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Olema Oncology (Inst); Pfizer; Takeda; Zai Lab

Research Funding - Amgen (Inst); AstraZeneca (Inst); BMSi (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly (Inst); MSD (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst)

Nadia  Harbeck

Stock and Other Ownership Interests  - West German Study Group

Honoraria - AstraZeneca; Daiichi-Sankyo; Gilead Sciences; Lilly; Menarini Group; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Viatris; Zuelligpharma

Consulting or Advisory Role - Gilead Sciences; IQVIA; Roche/Genentech; Springer; West German Study Group (I)

Speakers' Bureau - High5Oncology; Medscape; Springer Healthcare

Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Roche/Genentech (Inst)

Masato  Takahashi

Honoraria - AstraZeneca; Daiichi Sankyo/UCB Japan; Lilly; MSD; Pfizer

Seock-Ah  Im

Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; SK Biopharmaceutical

Research Funding - AstraZeneca (Inst); Boryung Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)

Other Relationship - Roche

(OPTIONAL) Uncompensated Relationships - Roche

Michael  Untch

Honoraria - AstraZeneca; Daiichi Sankyo; EurBio Scientific; Lilly; Menarini/Stemline Therapeutics; MSD; Myriad Genetics; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi Aventis GmbH

Consulting or Advisory Role - AstraZeneca; BeOne Medicines; Daiichi Sankyo; Lilly; Menarini/Stemline Therapeutics; MSD; Myriad Genetics; Novartis; Pfizer; Pierre Fabre; Roche; Sandoz Hexal; Sanofi Aventis Seagen

Peter  Fasching

Honoraria - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; SeaGen

Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Guardant Health; Hexal; Lilly; Menarini Group; Merck Sharp & Dohme; Mylan; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Veracyte

Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Pfizer (Inst); Roche

Fatima  Cardoso

Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Celgene; Daiichi Sankyo; Eisai; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline; IQvia; Macrogenics; Medscape; Merck Sharp & Dohme; Merus; Mundipharma; Mylan; Novartis; Pfizer; Pierre Fabre; Prime Oncology; Roche; Samsung Bioepis; Sanofi; Seagen; Teva; touchIME

Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer; Roche

Surui  Hou

Employment - Merck

Stock and Other Ownership Interests  - Merck

Usha  Malhotra

Employment - Merck

Leadership - Ricovr Healthcare Inc. (I)

Stock and Other Ownership Interests  - Merck; Ricovr Healthcare Inc. (I)

Francisco  Beca

Employment - Merck

Stock and Other Ownership Interests  - Merck

Joyce  O'Shaughnessy

Honoraria - AADi; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Oncology; DualityBio; Eisai; Ellipses Pharma; Exact Sciences; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; HiberCell; Jazz Pharmaceuticals; Johnson & Johnson; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics; Tempus; Tersera

Consulting or Advisory Role - AADi; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Oncology; DualityBio; Eisai; Ellipses Pharma; Exact Sciences; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; HiberCell; Jazz Pharmaceuticals; Johnson & Johnson; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics; Tempus; Tersera

Travel, Accommodations, Expenses - Aptitude Health; Daiichi Sankyo; DAVA Oncology; Lilly; Merck; Novartis